Chinook Therapeutics to Present at the 2021 RBC Capital Markets Global Healthcare Conference
Chinook Therapeutics, Inc. (Nasdaq: KDNY) announced participation in a virtual fireside chat at the RBC Capital Markets Global Healthcare Conference on May 19, 2021, at 10:55 am ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Chinook Therapeutics, Inc. (Nasdaq: KDNY) announced participation in a virtual fireside chat at the RBC Capital Markets Global Healthcare Conference on May 19, 2021, at 10:55 am ET. The event will provide insights into Chinook's focus on precision medicines for kidney diseases, including its lead program, atrasentan, a phase 3 endothelin receptor antagonist for IgA nephropathy. Archived recordings will be available on their website for 90 days. Chinook is developing innovative treatments for severe chronic kidney disorders, advancing several promising candidates.
Details
News Market Reaction – KDNY
The recorded move for KDNY in the trading session of this news was -0.93%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, May 13, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 10:55 am ET.
To access the live webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Chinook’s website. The archived webcast will remain available for replay on Chinook’s website for 90 days.
About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1b trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit www.chinooktx.com.
Contact:
Noopur Liffick
Vice President, Investor Relations & Corporate Communications
investors@chinooktx.com
media@chinooktx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.